PET, MRI study provides clues on Tourette Syndrome

11/21/2012 | Medscape (free registration)

Researchers using PET with carbon-11 flumazenil and structural MRI found that patients with Tourette Syndrome have lower binding of gamma-aminobutyric acid-ergic receptors in the ventral striatum, globus pallidus, thalamus, amygdala and right insula. The study findings are consistent with long-held theories about the disease concerning the disinhibition of particular circuits in the brain.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI